BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 25890498)

  • 21. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.
    Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G
    Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis.
    Zhang DM; Liu JS; Tang MK; Yiu A; Cao HH; Jiang L; Chan JY; Tian HY; Fung KP; Ye WC
    Eur J Pharmacol; 2012 Oct; 692(1-3):19-28. PubMed ID: 22841670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W; Xu B; Li Q; Jiang D; Yan S
    Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
    Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
    Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
    Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J
    Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.
    Wu JR; Hu CT; You RI; Ma PL; Pan SM; Lee MC; Wu WS
    PLoS One; 2015; 10(1):e0114495. PubMed ID: 25607934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of Rab17 promotes tumourigenic properties of hepatocellular carcinoma cells via Erk pathway.
    Qi J; Zhao P; Li F; Guo Y; Cui H; Liu A; Mao H; Zhao Y; Zhang X
    Int J Clin Exp Pathol; 2015; 8(5):4963-71. PubMed ID: 26191189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imperatorin induces Mcl-1 degradation to cooperatively trigger Bax translocation and Bak activation to suppress drug-resistant human hepatoma.
    Li X; Zeng X; Sun J; Li H; Wu P; Fung KP; Liu F
    Cancer Lett; 2014 Jun; 348(1-2):146-55. PubMed ID: 24680709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel matrine derivate inhibits differentiated human hepatoma cells and hepatic cancer stem-like cells by suppressing PI3K/AKT signaling pathways.
    Liu Y; Qi Y; Bai ZH; Ni CX; Ren QH; Xu WH; Xu J; Hu HG; Qiu L; Li JZ; He ZG; Zhang JP
    Acta Pharmacol Sin; 2017 Jan; 38(1):120-132. PubMed ID: 27773936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
    Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
    Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
    Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
    Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.
    Gopalan B; Narayanan K; Ke Z; Lu T; Zhang Y; Zhuo L
    Biomaterials; 2014 Aug; 35(26):7479-87. PubMed ID: 24912819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
    Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
    Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.
    Yin Y; Guo J; Teng F; Yu L; Jiang Y; Xie K; Jiang M; Fang J
    Drug Des Devel Ther; 2019; 13():4173-4184. PubMed ID: 31849449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
    Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
    Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory effects of interferon-β on hepatocellular carcinoma HepG2 via Akt/STAT phosphorylation.
    Ethiraj P; Veerappan K; Samuel S; Sivapatham S
    Fundam Clin Pharmacol; 2015 Jun; 29(3):278-85. PubMed ID: 25773664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.